

Stephen B Fox

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6055926/stephen-b-fox-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

310
papers

25,192
citations

78
h-index

153
g-index

326
ext. papers

28,795
ext. citations

6.9
avg, IF

6.34
L-index

#	Paper	IF	Citations
310	TRACEBACK: Testing of Historical Tubo-Ovarian Cancer Patients for Hereditary Risk Genes as a Cancer Prevention Strategy in Family Members.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2102108	2.2	
309	Findings from precision oncology in the clinic: rare, novel variants are a significant contributor to scaling molecular diagnostics.. <i>BMC Medical Genomics</i> , 2022 , 15, 70	3.7	0
308	BRAF Signaling Inhibition in Glioblastoma: Which Clinical Perspectives?. <i>Frontiers in Oncology</i> , 2021 , 11, 772052	5.3	0
307	SP142 PD-L1 Scoring Shows High Interobserver and Intraobserver Agreement in Triple-negative Breast Carcinoma But Overall Low Percentage Agreement With Other PD-L1 Clones SP263 and 22C3. <i>American Journal of Surgical Pathology</i> , 2021 , 45, 1108-1117	6.7	7
306	EGFR mutation profile in Australian patients with non-small cell lung cancer. <i>Pathology</i> , 2021 , 53, 933-936	6.6	1
305	The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. <i>Genetics in Medicine</i> , 2021 , 23, 1726-1737	8.1	2
304	Evaluation of Crizotinib Treatment in a Patient With Unresectable GOPC-ROS1 Fusion Agminated Spitz Nevus. <i>JAMA Dermatology</i> , 2021 , 157, 836-841	5.1	2
303	Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses. <i>Modern Pathology</i> , 2021 , 34, 194-206	9.8	6
302	Metaplastic carcinomas of the breast without evidence of epithelial differentiation: a diagnostic approach for management. <i>Histopathology</i> , 2021 , 78, 759-771	7.3	3
301	A MXI1-NUTM1 fusion protein with MYC-like activity suggests a novel oncogenic mechanism in a subset of NUTM1-rearranged tumors. <i>Laboratory Investigation</i> , 2021 , 101, 26-37	5.9	4
300	Interobserver variability in the assessment of stromal tumor-infiltrating lymphocytes (sTILs) in triple-negative invasive breast carcinoma influences the association with pathological complete response: the IVITA study. <i>Modern Pathology</i> , 2021 , 34, 2130-2140	9.8	2
299	Novel RET Fusion Predicts Response to Selective RET Inhibition With Selpercatinib in Malignant Pheochromocytoma.. <i>JCO Precision Oncology</i> , 2021 , 5, 1160-1165	3.6	1
298	Male breast cancer: an update. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021 , 1	5.1	1
297	In vitro and in vivo drug screens of tumor cells identify novel therapies for high-risk child cancer.. <i>EMBO Molecular Medicine</i> , 2021 , e14608	12	1
296	RAF1 rearrangements are common in pancreatic acinar cell carcinomas. <i>Modern Pathology</i> , 2020 , 33, 1811-1821	9.8	4
295	Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. <i>Npj Breast Cancer</i> , 2020 , 6, 17	7.8	54
294	ALK-Rearranged Non-Small Cell Lung Cancer in 2020: Real-World Triumphs in an Era of Multigeneration ALK-Inhibitor Sequencing Informed by Drug Resistance Profiling. <i>Oncologist</i> , 2020 , 25, 641-649	5.7	4

293	The genetic architecture of breast papillary lesions as a predictor of progression to carcinoma. <i>Npj Breast Cancer</i> , 2020 , 6, 9	7.8	13
292	The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice. <i>Journal of Pathology</i> , 2020 , 250, 667-684	9.4	83
291	Emerging entities in NUTM1-rearranged neoplasms. <i>Genes Chromosomes and Cancer</i> , 2020 , 59, 375-385	5	22
290	Improved next-generation sequencing pre-capture library yields and sequencing parameters using on-bead PCR. <i>BioTechniques</i> , 2020 , 68, 48-51	2.5	4
289	Preoperative EBlockade with Propranolol Reduces Biomarkers of Metastasis in Breast Cancer: A Phase II Randomized Trial. <i>Clinical Cancer Research</i> , 2020 , 26, 1803-1811	12.9	52
288	Using Genomic Sequencing to Explain an Exceptional Response to Therapy in a Malignant Phyllodes Tumor.. <i>JCO Precision Oncology</i> , 2020 , 4, 1263-1266	3.6	1
287	CUP-AI-Dx: A tool for inferring cancer tissue of origin and molecular subtype using RNA gene-expression data and artificial intelligence. <i>EBioMedicine</i> , 2020 , 61, 103030	8.8	15
286	Recurrent fusions in pediatric sarcoma and brain tumors. <i>Journal of Physical Education and Sports Management</i> , 2020 , 6,	2.8	2
285	Immune molecular profiling of a multiresistant primary prostate cancer with a neuroendocrine-like phenotype: a case report. <i>BMC Urology</i> , 2020 , 20, 171	2.2	4
284	Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. <i>American Journal of Human Genetics</i> , 2020 , 107, 837-848	11	12
283	The TP53 mutation rate differs in breast cancers that arise in women with high or low mammographic density. <i>Npj Breast Cancer</i> , 2020 , 6, 34	7.8	1
282	Clinical implications of prospective genomic profiling of metastatic breast cancer patients. <i>Breast Cancer Research</i> , 2020 , 22, 91	8.3	12
281	Interobserver variability in upfront dichotomous histopathological assessment of ductal carcinoma in situ of the breast: the DCISion study. <i>Modern Pathology</i> , 2020 , 33, 354-366	9.8	17
280	Dual Targeting of CDK4/6 and BCL2 Pathways Augments Tumor Response in Estrogen Receptor-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 4120-4134	12.9	29
279	The molecular origin and taxonomy of mucinous ovarian carcinoma. <i>Nature Communications</i> , 2019 , 10, 3935	17.4	59
278	CCL27/CCL28-CCR10 Chemokine Signaling Mediates Migration of Lymphatic Endothelial Cells. <i>Cancer Research</i> , 2019 , 79, 1558-1572	10.1	21
277	Retraction: The E3-ligase E6AP Represses Breast Cancer Metastasis via Regulation of ECT2-Rho Signaling. <i>Cancer Research</i> , 2019 , 79, 3008	10.1	1
276	CN spectator: a web-based tool for visualisation and clinical diagnosis of copy number variation from next generation sequencing. <i>Scientific Reports</i> , 2019 , 9, 6426	4.9	11

275	Atypical ductal hyperplasia is a multipotent precursor of breast carcinoma. <i>Journal of Pathology</i> , 2019 , 248, 326-338	9.4	12
274	Combined Tumor Sequencing and Case-Control Analyses of RAD51C in Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2019 , 111, 1332-1338	9.7	16
273	Molecular comparison of interval and screen-detected breast cancers. <i>Journal of Pathology</i> , 2019 , 248, 243-252	9.4	8
272	Profound MEK inhibitor response in a cutaneous melanoma harboring a GOLGA4-RAF1 fusion. <i>Journal of Clinical Investigation</i> , 2019 , 129, 1940-1945	15.9	19
271	MEK Inhibitor Therapy in Carcinomas With Fusions: Inferior Response in a Patient With Pancreatic Acinar Cell Carcinoma.. <i>JCO Precision Oncology</i> , 2019 , 3, 1-2	3.6	0
270	E6AP Promotes a Metastatic Phenotype in Prostate Cancer. <i>IScience</i> , 2019 , 22, 1-15	6.1	6
269	Exploring the feasibility and utility of exome-scale tumour sequencing in a clinical setting. <i>Internal Medicine Journal</i> , 2018 , 48, 786-794	1.6	3
268	Prognostic Significance of PD-L1 and CD8 Immune Cells in HPV Oropharyngeal Squamous Cell Carcinoma. <i>Cancer Immunology Research</i> , 2018 , 6, 295-304	12.5	65
267	Comparison of Four PD-L1 Immunohistochemical Assays in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 367-376	8.9	99
266	Survival difference according to mutation status in a prospective cohort study of Australian patients with metastatic non-small-cell lung carcinoma. <i>Internal Medicine Journal</i> , 2018 , 48, 37-44	1.6	8
265	SDH-deficient renal cell carcinoma associated with biallelic mutation in succinate dehydrogenase A: comprehensive genetic profiling and its relation to therapy response. <i>Npj Precision Oncology</i> , 2018 , 2, 9	9.8	14
264	Determinants of variability of five programmed death ligand-1 immunohistochemistry assays in non-small cell lung cancer samples. <i>Oncotarget</i> , 2018 , 9, 6841-6851	3.3	13
263	Frequent activating STAT3 mutations and novel recurrent genomic abnormalities detected in breast implant-associated anaplastic large cell lymphoma. <i>Oncotarget</i> , 2018 , 9, 36126-36136	3.3	43
262	Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis. <i>Nature Medicine</i> , 2018 , 24, 986-993	50.5	420
261	Invasion in breast lesions: the role of the epithelial-stroma barrier. <i>Histopathology</i> , 2018 , 72, 1075-1083	7.3	13
260	Precision oncology using a clinician-directed, tailored approach to molecular profiling. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018 , 14, 84-90	1.9	1
259	Response to Editorial: The PD-L1 Immunohistochemistry Biomarker: Two Steps Forward, One Step Back?. <i>Journal of Thoracic Oncology</i> , 2018 , 13, e185-e186	8.9	1
258	Mapping the EORTC-QLQ-C30 to the EQ-5D-3L: An Assessment of Existing and Newly Developed Algorithms. <i>Medical Decision Making</i> , 2018 , 38, 954-967	2.5	10

257	Cost-effectiveness of precision medicine in the fourth-line treatment of metastatic lung adenocarcinoma: An early decision analytic model of multiplex targeted sequencing. <i>Lung Cancer</i> , 2017 , 107, 22-35	5.9	21
256	MDM4 is a rational target for treating breast cancers with mutant p53. <i>Journal of Pathology</i> , 2017 , 241, 661-670	9.4	24
255	Reduced abundance of the E3 ubiquitin ligase E6AP contributes to decreased expression of the INK4/ARF locus in non-small cell lung cancer. <i>Science Signaling</i> , 2017 , 10,	8.8	19
254	GATA3 expression in triple-negative breast cancers. <i>Histopathology</i> , 2017 , 71, 63-71	7.3	9
253	Multiplexed transcriptome analysis to detect ALK, ROS1 and RET rearrangements in lung cancer. <i>Scientific Reports</i> , 2017 , 7, 42259	4.9	38
252	Intra- and Interobserver Reproducibility Assessment of PD-L1 Biomarker in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 4569-4577	12.9	65
251	Relationship of the Breast Ductal Carcinoma Immune Microenvironment with Clinicopathological and Genetic Features. <i>Clinical Cancer Research</i> , 2017 , 23, 5210-5217	12.9	41
250	PathOS: a decision support system for reporting high throughput sequencing of cancers in clinical diagnostic laboratories. <i>Genome Medicine</i> , 2017 , 9, 38	14.4	20
249	Combined immune checkpoint blockade as a therapeutic strategy for -mutated breast cancer. <i>Science Translational Medicine</i> , 2017 , 9,	17.5	167
248	Cisplatin Increases Sensitivity to FGFR Inhibition in Patient-Derived Xenograft Models of Lung Squamous Cell Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2017 , 16, 1610-1622	6.1	16
247	Breast ductal carcinoma in situ carry mutational driver events representative of invasive breast cancer. <i>Modern Pathology</i> , 2017 , 30, 952-963	9.8	37
246	Cousins not twins: intratumoural and intertumoural heterogeneity in syndromic neuroendocrine tumours. <i>Journal of Pathology</i> , 2017 , 242, 273-283	9.4	6
245	Blood-based detection of RAS mutations to guide anti-EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue-based RAS testing. <i>Molecular Oncology</i> , 2017 , 11, 208-219	7.9	83
244	Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. <i>Lancet Oncology, The</i> , 2017 , 18, 52-62	21.7	164
243	Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer. <i>Pathology</i> , 2017 , 49, 141-155	1.6	68
242	Genome-wide functional analysis reveals central signaling regulators of lymphatic endothelial cell migration and remodeling. <i>Science Signaling</i> , 2017 , 10,	8.8	17
241	BRCA2 carriers with male breast cancer show elevated tumour methylation. <i>BMC Cancer</i> , 2017 , 17, 641	4.8	4
240	Canary: an atomic pipeline for clinical amplicon assays. <i>BMC Bioinformatics</i> , 2017 , 18, 555	3.6	2

239	HER2 testing in advanced gastric and gastro-oesophageal cancer: analysis of an Australia-wide testing program. <i>Pathology</i> , 2017 , 49, 575-581	1.6	8
238	The fibrinolysis inhibitor E2-plasmin restricts lymphatic remodelling and metastasis in a mouse model of cancer. <i>Growth Factors</i> , 2017 , 35, 61-75	1.6	6
237	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinomas of the Head and Neck, Genitourinary Carcinomas and Primary Brain Tumors. <i>Advances in Anatomic Pathology</i> , 2017 , 24, 311-335	5.1	299
236	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. <i>Advances in Anatomic Pathology</i> , 2017 , 24, 311-335	5.1	293
235	Lessons learnt from implementation of a Lynch syndrome screening program for patients with gynaecological malignancy. <i>Pathology</i> , 2017 , 49, 457-464	1.6	25
234	Ductal Carcinoma Biology, Biomarkers, and Diagnosis. <i>Frontiers in Oncology</i> , 2017 , 7, 248	5.3	61
233	E6AP promotes prostate cancer by reducing p27 expression. <i>Oncotarget</i> , 2017 , 8, 42939-42948	3.3	19
232	LRH-1 expression patterns in breast cancer tissues are associated with tumour aggressiveness. <i>Oncotarget</i> , 2017 , 8, 83626-83636	3.3	11
231	Hypoxia-related biological markers as predictors of epirubicin-based treatment responsiveness and resistance in locally advanced breast cancer. <i>Oncotarget</i> , 2017 , 8, 78870-78881	3.3	4
230	Immunomodulation by MYB is associated with tumor relapse in patients with early stage colorectal cancer. <i>Oncology</i> , 2016 , 5, e1149667	7.2	8
229	Restoration of tumor suppression in prostate cancer by targeting the E3 ligase E6AP. <i>Oncogene</i> , 2016 , 35, 6235-6245	9.2	22
228	Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with T2 to T4, N0 and N1 breast cancer. <i>Breast</i> , 2016 , 29, 55-61	3.6	3
227	Mammographically dense human breast tissue stimulates MCF10DCIS.com progression to invasive lesions and metastasis. <i>Breast Cancer Research</i> , 2016 , 18, 106	8.3	8
226	Copy number analysis by low coverage whole genome sequencing using ultra low-input DNA from formalin-fixed paraffin embedded tumor tissue. <i>Genome Medicine</i> , 2016 , 8, 121	14.4	27
225	Differential expression of immunohistochemical markers in primary lung and breast cancers enriched for triple-negative tumours. <i>Histopathology</i> , 2016 , 68, 367-77	7.3	13
224	Ductal carcinoma in situ - update on risk assessment and management. <i>Histopathology</i> , 2016 , 68, 96-109	7.3	34
223	The Subclonal Architecture of Metastatic Breast Cancer: Results from a Prospective Community-Based Rapid Autopsy Program "CASCADE". <i>PLoS Medicine</i> , 2016 , 13, e1002204	11.6	81
222	Biobanking in Cancer Research 2016 , 27-49		1

221	The Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor Microenvironment. <i>Frontiers in Immunology</i> , 2016 , 7, 621	8.4	90
220	Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. <i>Modern Pathology</i> , 2016 , 29, 1155-64	9.8	154
219	Apatinib for the treatment of gastric cancer. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016 , 10, 887-92	4.2	38
218	Reply to the Baader-Mein Hof phenomenon in ductal carcinoma in situ of the breast. <i>Histopathology</i> , 2016 , 69, 523-4	7.3	1
217	The E3-ligase E6AP Represses Breast Cancer Metastasis via Regulation of ECT2-Rho Signaling. <i>Cancer Research</i> , 2016 , 76, 4236-48	10.1	25
216	Assessing Tumor Angiogenesis in Histological Samples. <i>Methods in Molecular Biology</i> , 2016 , 1430, 3-33	1.4	3
215	KRAS mutation testing in colorectal cancer: the model for molecular pathology testing in the future. <i>Colorectal Cancer</i> , 2016 , 5, 73-80	0.8	
214	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. <i>Breast Cancer Research</i> , 2016 , 18, 15	8.3	58
213	Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials. <i>European Journal of Cancer</i> , 2016 , 61, 111-21	7.5	41
212	Determining HER2 (ERBB2) amplification status in women with breast cancer: final results from the Australian in situ hybridisation program. <i>Pathology</i> , 2016 , 48, 535-42	1.6	6
211	VEGF-D promotes pulmonary oedema in hyperoxic acute lung injury. <i>Journal of Pathology</i> , 2016 , 239, 152-61	9.4	18
210	The cancer genetics and pathology of male breast cancer. <i>Histopathology</i> , 2016 , 68, 110-8	7.3	35
209	Breast lesions of uncertain malignant nature and limited metastatic potential: proposals to improve their recognition and clinical management. <i>Histopathology</i> , 2016 , 68, 45-56	7.3	29
208	Phyllodes tumours of the breast: a consensus review. <i>Histopathology</i> , 2016 , 68, 5-21	7.3	220
207	Assessing the clinical value of targeted massively parallel sequencing in a longitudinal, prospective population-based study of cancer patients. <i>British Journal of Cancer</i> , 2015 , 112, 1411-20	8.7	44
206	The genomic landscape of pheochromocytoma. <i>Journal of Pathology</i> , 2015 , 236, 78-89	9.4	51
205	Effect of Primary Letrozole Treatment on Tumor Expression of mTOR and HIF-1 α and Relation to Clinical Response. <i>Journal of the National Cancer Institute Monographs</i> , 2015 , 2015, 64-6	4.8	4
204	Low-grade fibromatosis-like spindle cell carcinomas of the breast are molecularly exiguous. <i>Journal of Clinical Pathology</i> , 2015 , 68, 362-7	3.9	15

203	Large genomic rearrangements in the familial breast and ovarian cancer gene BRCA1 are associated with an increased frequency of high risk features. <i>Familial Cancer</i> , 2015 , 14, 287-95	3	17
202	Comparison of methods in the detection of ALK and ROS1 rearrangements in lung cancer. <i>Journal of Thoracic Oncology</i> , 2015 , 10, 611-8	8.9	55
201	Clinical cancer genomic analysis: data engineering required. <i>Lancet Oncology, The</i> , 2015 , 16, 1015-1017	21.7	5
200	Cancer 2015: a longitudinal whole-of-system study of genomic cancer medicine. <i>Drug Discovery Today</i> , 2015 , 20, 1429-32	8.8	1
199	Comparative microRNA profiling of sporadic and BRCA1 associated basal-like breast cancers. <i>BMC Cancer</i> , 2015 , 15, 506	4.8	11
198	Targeting Mdmx to treat breast cancers with wild-type p53. <i>Cell Death and Disease</i> , 2015 , 6, e1821	9.8	28
197	Copy number analysis of ductal carcinoma in situ with and without recurrence. <i>Modern Pathology</i> , 2015 , 28, 1174-84	9.8	28
196	Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer. <i>British Journal of Cancer</i> , 2015 , 112, 52-60	8.7	23
195	Appraisal of the technologies and review of the genomic landscape of ductal carcinoma in situ of the breast. <i>Breast Cancer Research</i> , 2015 , 17, 80	8.3	5
194	In Response. <i>Journal of Thoracic Oncology</i> , 2015 , 10, e85	8.9	
193	Assessment of DNA methylation profiling and copy number variation as indications of clonal relationship in ipsilateral and contralateral breast cancers to distinguish recurrent breast cancer from a second primary tumour. <i>BMC Cancer</i> , 2015 , 15, 669	4.8	11
192	Altered significance of DAmico risk classification in patients with prostate cancer linked to a familial breast cancer (kConFab) cohort. <i>BJU International</i> , 2015 , 116, 207-12	5.6	4
191	Applicability of next generation sequencing technology in microsatellite instability testing. <i>Genes</i> , 2015 , 6, 46-59	4.2	34
190	"Cancer 2015": A Prospective, Population-Based Cancer Cohort-Phase 1: Feasibility of Genomics-Guided Precision Medicine in the Clinic. <i>Journal of Personalized Medicine</i> , 2015 , 5, 354-69	3.6	8
189	Breast Tissue Composition and Immunophenotype and Its Relationship with Mammographic Density in Women at High Risk of Breast Cancer. <i>PLoS ONE</i> , 2015 , 10, e0128861	3.7	17
188	Neoadjuvant Model in Cancer Treatment: From Clinical Opportunity to Health-Care Utility. <i>Journal of the National Cancer Institute Monographs</i> , 2015 , 2015, 1-3	4.8	
187	UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas. <i>Cancer Research</i> , 2015 , 75, 5228-34	10.1	196
186	Would the combination of everolimus with endocrine-therapy help in FGFR2 positive serous endometrial cancer?. <i>Oncoscience</i> , 2015 , 2, 567-9	0.8	1

185	Molecular methods for somatic mutation testing in lung adenocarcinoma: EGFR and beyond. <i>Translational Lung Cancer Research</i> , 2015 , 4, 126-41	4.4	48
184	Lymphangiogenesis and lymphatic vessel remodelling in cancer. <i>Nature Reviews Cancer</i> , 2014 , 14, 159-72	3.13	467
183	Pure anti-tumor effect of zoledronic acid in naïve bone-only metastatic and locally advanced breast cancer: proof from the "biological window therapy". <i>Breast Cancer Research and Treatment</i> , 2014 , 144, 113-21	4.4	13
182	KRAS mutation testing of metastatic colorectal cancer in Australia: where are we at?. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2014 , 10, 261-5	1.9	4
181	Nuclear HIF1A expression is strongly prognostic in sporadic but not familial male breast cancer. <i>Modern Pathology</i> , 2014 , 27, 1223-30	9.8	17
180	Differential mechanisms of CDKN2A (p16) alteration in oral tongue squamous cell carcinomas and correlation with patient outcome. <i>International Journal of Cancer</i> , 2014 , 135, 887-95	7.5	42
179	COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment. <i>British Journal of Cancer</i> , 2014 , 111, 46-54	8.7	30
178	Expression of E6AP and PML predicts for prostate cancer progression and cancer-specific death. <i>Annals of Oncology</i> , 2014 , 25, 2392-2397	10.3	17
177	RAD21 cohesin overexpression is a prognostic and predictive marker exacerbating poor prognosis in KRAS mutant colorectal carcinomas. <i>British Journal of Cancer</i> , 2014 , 110, 1606-13	8.7	37
176	Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts. <i>Molecular Oncology</i> , 2014 , 8, 656-68	7.9	97
175	Sequence artefacts in a prospective series of formalin-fixed tumours tested for mutations in hotspot regions by massively parallel sequencing. <i>BMC Medical Genomics</i> , 2014 , 7, 23	3.7	170
174	Targeting fibroblast growth factor receptor in breast cancer: a promise or a pitfall?. <i>Expert Opinion on Therapeutic Targets</i> , 2014 , 18, 665-78	6.4	8
173	Role of p53 in the progression of gastric cancer. <i>Oncotarget</i> , 2014 , 5, 12016-26	3.3	51
172	Molecular profiling in colorectal cancer: current state of play and future directions. <i>Colorectal Cancer</i> , 2014 , 3, 41-56	0.8	1
171	A phase Ib/II translational study of sunitinib with neoadjuvant radiotherapy in soft-tissue sarcoma. <i>British Journal of Cancer</i> , 2014 , 111, 2254-61	8.7	39
170	Diagnostic issues with significant tumour displacement in breast biopsies. <i>Journal of Clinical Pathology</i> , 2014 , 67, 1110-1	3.9	
169	Cohesin Rad21 mediates loss of heterozygosity and is upregulated via Wnt promoting transcriptional dysregulation in gastrointestinal tumors. <i>Cell Reports</i> , 2014 , 9, 1781-1797	10.6	31
168	Controversies in the management of gastrointestinal stromal tumors. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2014 , 10, 216-27	1.9	4

167	National Working Group Meeting on ALK diagnostics in lung cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2014 , 10 Suppl 2, 11-7	1.9	9
166	Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines. <i>Pigment Cell and Melanoma Research</i> , 2014 , 27, 590-600	4.5	133
165	Mutational profiling of familial male breast cancers reveals similarities with luminal A female breast cancer with rare TP53 mutations. <i>British Journal of Cancer</i> , 2014 , 111, 2351-60	8.7	17
164	Methylation profiling of ductal carcinoma in situ and its relationship to histopathological features. <i>Breast Cancer Research</i> , 2014 , 16, 423	8.3	16
163	HER2 status in gastric/gastro-oesophageal junctional cancers: should determination of gene amplification by SISH use HER2 copy number or HER2: CEP17 ratio?. <i>Pathology</i> , 2014 , 46, 184-7	1.6	8
162	Mutations in EGFR, BRAF and RAS are rare in triple-negative and basal-like breast cancers from Caucasian women. <i>Breast Cancer Research and Treatment</i> , 2014 , 143, 385-92	4.4	43
161	Blood vessel invasion and other variables as predictors of long-term survival in Japanese and British patients with primary invasive breast cancer. <i>International Journal of Clinical and Experimental Pathology</i> , 2014 , 7, 7967-78	1.4	4
160	Frequency of fibroblast growth factor receptor 1 gene amplification in oral tongue squamous cell carcinomas and associations with clinical features and patient outcome. <i>Oral Oncology</i> , 2013 , 49, 576-81	4.4	28
159	Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization. <i>Modern Pathology</i> , 2013 , 26, 1545-53	9.8	119
158	PIK3CA mutations are frequently observed in BRCA1 but not BRCA2-associated male breast cancer. <i>Breast Cancer Research</i> , 2013 , 15, R69	8.3	18
157	Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary. <i>Journal of Pathology</i> , 2013 , 231, 413-23	9.4	73
156	DNA methylation in ductal carcinoma in situ of the breast. <i>Breast Cancer Research</i> , 2013 , 15, 206	8.3	16
155	HER2-positive breast cancer metastatic to intracranial meningioma: a case report. <i>Journal of Clinical Pathology</i> , 2013 , 66, 633-4	3.9	5
154	HIF-1 β stimulates aromatase expression driven by prostaglandin E2 in breast adipose stroma. <i>Breast Cancer Research</i> , 2013 , 15, R30	8.3	40
153	Loss of PML cooperates with mutant p53 to drive more aggressive cancers in a gender-dependent manner. <i>Cell Cycle</i> , 2013 , 12, 1722-31	4.7	19
152	The G-protein-coupled receptor CLR is upregulated in an autocrine loop with adrenomedullin in clear cell renal cell carcinoma and associated with poor prognosis. <i>Clinical Cancer Research</i> , 2013 , 19, 5740-8	12.9	15
151	Multomics medicine in oncology: assessing effectiveness, cost-effectiveness and future research priorities for the molecularly unique individual. <i>Pharmacogenomics</i> , 2013 , 14, 1405-17	2.6	12
150	Metastatic gastrointestinal stromal tumour of the ileum with dual primary c-KIT missense mutations. <i>Pathology</i> , 2013 , 45, 604-6	1.6	1

149	Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer. <i>British Journal of Cancer</i> , 2013 , 108, 1587-92	8.7	45
148	A multisite blinded study for the detection of BRAF mutations in formalin-fixed, paraffin-embedded malignant melanoma. <i>Scientific Reports</i> , 2013 , 3, 1659	4.9	31
147	Lobular neoplasia of the breast revisited with emphasis on the role of E-cadherin immunohistochemistry. <i>American Journal of Surgical Pathology</i> , 2013 , 37, e1-11	6.7	109
146	Triple negative breast cancers have a reduced expression of DNA repair genes. <i>PLoS ONE</i> , 2013 , 8, e66243	5.7	27
145	A fully human inhibitory monoclonal antibody to the Wnt receptor RYK. <i>PLoS ONE</i> , 2013 , 8, e75447	3.7	18
144	E6AP ubiquitin ligase regulates PML-induced senescence in Myc-driven lymphomagenesis. <i>Blood</i> , 2012 , 120, 822-32	2.2	45
143	Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. <i>Lancet Oncology</i> , 2012 , 13, 1011-9	21.7	983
142	Enhanced RAD21 cohesin expression confers poor prognosis in BRCA2 and BRCA1, but not BRCA1 familial breast cancers. <i>Breast Cancer Research</i> , 2012 , 14, R69	8.3	32
141	A prospective pathologic study to define the clinical target volume for partial breast radiation therapy in women with early breast cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012 , 84, 1116-22	4	8
140	Genotypic and phenotypic analysis of familial male breast cancer shows under representation of the HER2 and basal subtypes in BRCA-associated carcinomas. <i>BMC Cancer</i> , 2012 , 12, 510	4.8	37
139	High grade prostatic intraepithelial neoplasia does not display loss of heterozygosity at the mutation locus in BRCA2 mutation carriers with aggressive prostate cancer. <i>BJU International</i> , 2012 , 110, E1181-6	5.6	6
138	Correlation of Ataxia-Telangiectasia-Mutated (ATM) gene loss with outcome in head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2012 , 48, 698-702	4.4	8
137	BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2654-63	2.2	810
136	Assessing HER2 amplification in breast cancer: findings from the Australian In Situ Hybridization Program. <i>Breast Cancer Research and Treatment</i> , 2012 , 134, 617-24	4.4	25
135	VEGF-D promotes tumor metastasis by regulating prostaglandins produced by the collecting lymphatic endothelium. <i>Cancer Cell</i> , 2012 , 21, 181-95	24.3	208
134	Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 2766-71	11.5	156
133	The molecular characterisation of unusual subcutaneous spindle cell lesion of breast. <i>Journal of Clinical Pathology</i> , 2012 , 65, 746-50	3.9	2
132	Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012 , 21, 134-47	4	411

131	Gastric HER2 Testing Study (GaTHER): an evaluation of gastric/gastroesophageal junction cancer testing accuracy in Australia. <i>American Journal of Surgical Pathology</i> , 2012 , 36, 577-82	6.7	38
130	The connection between lymphangiogenic signalling and prostaglandin biology: a missing link in the metastatic pathway. <i>Oncotarget</i> , 2012 , 3, 893-906	3.3	41
129	Enhanced RAD21 cohesin expression confers poor prognosis and resistance to chemotherapy in high grade luminal, basal and HER2 breast cancers. <i>Breast Cancer Research</i> , 2011 , 13, R9	8.3	62
128	Contribution of large genomic BRCA1 alterations to early-onset breast cancer selected for family history and tumour morphology: a report from The Breast Cancer Family Registry. <i>Breast Cancer Research</i> , 2011 , 13, R14	8.3	9
127	The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1 α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen. <i>Breast Cancer Research</i> , 2011 , 13, R16	8.3	21
126	The expression of the ubiquitin ligase SIAH2 (seven in absentia homolog 2) is mediated through gene copy number in breast cancer and is associated with a basal-like phenotype and p53 expression. <i>Breast Cancer Research</i> , 2011 , 13, R19	8.3	37
125	Recruitment of regulatory T cells is correlated with hypoxia-induced CXCR4 expression, and is associated with poor prognosis in basal-like breast cancers. <i>Breast Cancer Research</i> , 2011 , 13, R47	8.3	124
124	Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. <i>Breast Cancer Research</i> , 2011 , 13, R110	8.3	62
123	Leukocyte adhesion-GPCR EMR2 is aberrantly expressed in human breast carcinomas and is associated with patient survival. <i>Oncology Reports</i> , 2011 , 25, 619-27	3.5	32
122	The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene. <i>Oncogene</i> , 2011 , 30, 2810-22	9.2	212
121	Nuclear and cytoplasmic expressions of ER α and ER β are predictive of response to therapy and alters prognosis in familial breast cancers. <i>Breast Cancer Research and Treatment</i> , 2011 , 126, 395-405	4.4	44
120	"Overcoming breast cancer drug resistance with mTOR inhibitors". Could it be a myth or a real possibility in the short-term future?. <i>Breast Cancer Research and Treatment</i> , 2011 , 128, 599-606	4.4	43
119	Aberrant DNA methylation but not mutation of CITED4 is associated with alteration of HIF-regulated genes in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011 , 130, 319-29	4.4	14
118	A high-throughput protocol for mutation scanning of the BRCA1 and BRCA2 genes. <i>BMC Cancer</i> , 2011 , 11, 265	4.8	25
117	Antitumor activities and on-target toxicities mediated by a TRAIL receptor agonist following cotreatment with panobinostat. <i>International Journal of Cancer</i> , 2011 , 128, 2735-47	7.5	9
116	Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. <i>Modern Pathology</i> , 2011 , 24, 157-67	9.8	447
115	Nuclear localization of factor inhibitor hypoxia-inducible factor in prostate cancer is associated with poor prognosis. <i>Journal of Urology</i> , 2011 , 185, 1513-8	2.5	9
114	Gata-3 negatively regulates the tumor-initiating capacity of mammary luminal progenitor cells and targets the putative tumor suppressor caspase-14. <i>Molecular and Cellular Biology</i> , 2011 , 31, 4609-22	4.8	84

113	Positron emission tomography and neoadjuvant therapy of breast cancer. <i>Journal of the National Cancer Institute Monographs</i> , 2011 , 2011, 111-5	4.8	5
112	Relationship between epidermal growth factor receptor status, p16(INK4A), and outcome in head and neck squamous cell carcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011 , 20, 1230-7	4	72
111	Decreased prostate cancer-specific survival of men with BRCA2 mutations from multiple breast cancer families. <i>Cancer Prevention Research</i> , 2011 , 4, 1002-10	3.2	82
110	Molecular oncology and the neoadjuvant setting: the perfect blend for treatment personalization and clinical trial design. <i>Journal of the National Cancer Institute Monographs</i> , 2011 , 2011, 67-70	4.8	4
109	kConFab: a familial breast cancer consortium facilitating research and translational oncology. <i>Journal of the National Cancer Institute Monographs</i> , 2011 , 2011, 79-81	4.8	11
108	MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4803-10	2.2	364
107	Constitutional methylation of the BRCA1 promoter is specifically associated with BRCA1 mutation-associated pathology in early-onset breast cancer. <i>Cancer Prevention Research</i> , 2011 , 4, 23-33	3.2	121
106	International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). <i>Journal of the National Cancer Institute Monographs</i> , 2011 , 2011, 147-51	4.8	55
105	Predictive immunohistochemical biomarkers in the context of neoadjuvant therapy for breast cancer. <i>Journal of the National Cancer Institute Monographs</i> , 2011 , 2011, 99-102	4.8	6
104	DNA methylation analysis of the HIF-1 α prolyl hydroxylase domain genes PHD1, PHD2, PHD3 and the factor inhibiting HIF gene FIH in invasive breast carcinomas. <i>Histopathology</i> , 2010 , 57, 451-60	7.3	14
103	Establishment of the Australian in situ hybridization program for the assessment of HER2 amplification in breast cancer: a model for the introduction of new biomarkers into clinical practice. <i>Diagnostic Molecular Pathology</i> , 2010 , 19, 187-93		10
102	The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3. <i>Cancer Research</i> , 2010 , 70, 1573-84	10.1	124
101	Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. <i>Journal of Clinical Oncology</i> , 2010 , 28, 4142-8	2.2	593
100	HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer. <i>Breast Cancer Research</i> , 2010 , 12, R46	8.3	87
99	Breast cancer prognostic classification in the molecular era: the role of histological grade. <i>Breast Cancer Research</i> , 2010 , 12, 207	8.3	459
98	Subtypes of familial breast tumours revealed by expression and copy number profiling. <i>Breast Cancer Research and Treatment</i> , 2010 , 123, 661-77	4.4	81
97	Synergistic activity of letrozole and sorafenib on breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2010 , 124, 79-88	4.4	32
96	DNA methylation profiling of phyllodes and fibroadenoma tumours of the breast. <i>Breast Cancer Research and Treatment</i> , 2010 , 124, 555-65	4.4	31

95	Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2010 , 123, 795-804	4.4	11
94	No evidence for DNA methylation of von Hippel-Lindau ubiquitin ligase complex genes in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2010 , 124, 853-6	4.4	2
93	Loss of STARD10 expression identifies a group of poor prognosis breast cancers independent of HER2/Neu and triple negative status. <i>International Journal of Cancer</i> , 2010 , 126, 1445-53	7.5	11
92	A multiplex endpoint RT-PCR assay for quality assessment of RNA extracted from formalin-fixed paraffin-embedded tissues. <i>BMC Biotechnology</i> , 2010 , 10, 89	3.5	14
91	Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients. <i>Clinical Cancer Research</i> , 2009 , 15, 1046-51	12.9	106
90	Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. <i>Clinical Cancer Research</i> , 2009 , 15, 1417-27	12.9	217
89	Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 227-34	2.2	98
88	No evidence for promoter region methylation of the succinate dehydrogenase and fumarate hydratase tumour suppressor genes in breast cancer. <i>BMC Research Notes</i> , 2009 , 2, 194	2.3	11
87	Does cyclin D1 discriminate between BRCA2 and BRCA1 breast cancers?. <i>Histopathology</i> , 2009 , 55, 625-67.3		2
86	Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. <i>Nature Medicine</i> , 2009 , 15, 907-13	50.5	1034
85	The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy. <i>British Journal of Cancer</i> , 2009 , 100, 405-11	8.7	150
84	BRCA1 tumours correlate with a HIF-1alpha phenotype and have a poor prognosis through modulation of hydroxylase enzyme profile expression. <i>British Journal of Cancer</i> , 2009 , 101, 1168-74	8.7	51
83	Expression of delta-like ligand 4 (Dll4) and markers of hypoxia in colon cancer. <i>British Journal of Cancer</i> , 2009 , 101, 1749-57	8.7	90
82	Assessing tumor angiogenesis in histological samples. <i>Methods in Molecular Biology</i> , 2009 , 467, 55-78	1.4	8
81	A multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting. <i>Journal of Molecular Diagnostics</i> , 2009 , 11, 543-52	5.1	92
80	BRCA1 associated breast cancers are frequently positive for ER and its cytoplasmic expression confers a poor prognosis. <i>Pathology</i> , 2009 , 41, 51	1.6	
79	A randomized controlled trial investigating the effects of celecoxib in patients with localized prostate cancer. <i>Anticancer Research</i> , 2009 , 29, 1483-8	2.3	40
78	Absence of retroviral vector-mediated transformation of gene-modified T cells after long-term engraftment in mice. <i>Gene Therapy</i> , 2008 , 15, 1056-66	4	23

77	No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas. <i>Nature Genetics</i> , 2008 , 40, 650-5	36.3	230
76	High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies. <i>BMC Cancer</i> , 2008 , 8, 142	4.8	161
75	Rapid detection of carriers with BRCA1 and BRCA2 mutations using high resolution melting analysis. <i>BMC Cancer</i> , 2008 , 8, 59	4.8	63
74	Detection of the transforming AKT1 mutation E17K in non-small cell lung cancer by high resolution melting. <i>BMC Research Notes</i> , 2008 , 1, 14	2.3	35
73	Down-regulation of phosphatidylinositol 3Pkinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer. <i>Clinical Cancer Research</i> , 2008 , 14, 2673-80	12.9	49
72	Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. <i>Clinical Cancer Research</i> , 2008 , 14, 5198-208	12.9	1044
71	Expression of the forkhead transcription factor FOXP1 is associated with that of estrogen receptor-beta in primary invasive breast carcinomas. <i>Breast Cancer Research and Treatment</i> , 2008 , 111, 453-9	4.4	43
70	Expression of BNIP3 correlates with hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha and the androgen receptor in prostate cancer and is regulated directly by hypoxia but not androgens in cell lines. <i>Prostate</i> , 2008 , 68, 336-43	4.2	16
69	Consensus approaches to best practice management of gastrointestinal stromal tumors. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2008 , 4, 188-198	1.9	3
68	The number of regulatory T cells in prostate cancer is associated with the androgen receptor and hypoxia-inducible factor (HIF)-2alpha but not HIF-1alpha. <i>Prostate</i> , 2007 , 67, 623-9	4.2	28
67	Expression of the forkhead transcription factor FOXP1 is associated both with hypoxia inducible factors (HIFs) and the androgen receptor in prostate cancer but is not directly regulated by androgens or hypoxia. <i>Prostate</i> , 2007 , 67, 1091-8	4.2	38
66	Selective silencing of the hypoxia-inducible factor 1 target gene BNIP3 by histone deacetylation and methylation in colorectal cancer. <i>Oncogene</i> , 2007 , 26, 132-41	9.2	55
65	High resolution melting for mutation scanning of TP53 exons 5-8. <i>BMC Cancer</i> , 2007 , 7, 168	4.8	108
64	RANKL-dependent and RANKL-independent mechanisms of macrophage-osteoclast differentiation in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2007 , 105, 7-16	4.4	32
63	EGFR mutations in exons 18-21 in sporadic breast cancer. <i>Annals of Oncology</i> , 2007 , 18, 203-205	10.3	23
62	BNIP3 as a progression marker in primary human breast cancer; opposing functions in in situ versus invasive cancer. <i>Clinical Cancer Research</i> , 2007 , 13, 467-74	12.9	72
61	Regulation of hepatocyte growth factor activator inhibitor 2 by hypoxia in breast cancer. <i>Clinical Cancer Research</i> , 2007 , 13, 550-8	12.9	12
60	Quantification and localisation of FOXP3+ T lymphocytes and relation to hepatic inflammation during chronic HCV infection. <i>Journal of Hepatology</i> , 2007 , 47, 316-24	13.4	129

59	Breast tumour angiogenesis. <i>Breast Cancer Research</i> , 2007 , 9, 216	8.3	117
58	Cytoplasmic location of factor-inhibiting hypoxia-inducible factor is associated with an enhanced hypoxic response and a shorter survival in invasive breast cancer. <i>Breast Cancer Research</i> , 2007 , 9, R89	8.3	34
57	Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer. <i>Clinical Cancer Research</i> , 2006 , 12, 4562-8	12.9	198
56	Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. <i>Journal of Clinical Oncology</i> , 2006 , 24, 3623-8	2.2	156
55	Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer. <i>Endocrine-Related Cancer</i> , 2006 , 13, 921-30	5.7	60
54	Adrenomedullin and CGRP interact with endogenous calcitonin-receptor-like receptor in endothelial cells and induce its desensitisation by different mechanisms. <i>Journal of Cell Science</i> , 2006 , 119, 910-22	5.3	40
53	First international consensus on the methodology of lymphangiogenesis quantification in solid human tumours. <i>British Journal of Cancer</i> , 2006 , 95, 1611-25	8.7	161
52	Adrenomedullin and tumour angiogenesis. <i>British Journal of Cancer</i> , 2006 , 94, 1-7	8.7	109
51	Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. <i>Journal of the National Cancer Institute</i> , 2006 , 98, 262-72	9.7	1485
50	Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. <i>Journal of Clinical Oncology</i> , 2006 , 24, 5373-80	2.2	841
49	Quantitative angiogenesis in breast cancer. <i>Methods in Molecular Medicine</i> , 2006 , 120, 161-87		6
48	Distinct molecular signature of inflammatory breast cancer by cDNA microarray analysis. <i>Breast Cancer Research and Treatment</i> , 2005 , 93, 237-46	4.4	92
47	Angiogenin is up-regulated in the nucleus and cytoplasm in human primary breast carcinoma and is associated with markers of hypoxia but not survival. <i>Journal of Pathology</i> , 2005 , 205, 585-91	9.4	39
46	The androgen receptor is significantly associated with vascular endothelial growth factor and hypoxia sensing via hypoxia-inducible factors HIF-1a, HIF-2a, and the prolyl hydroxylases in human prostate cancer. <i>Clinical Cancer Research</i> , 2005 , 11, 7658-63	12.9	128
45	Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification. <i>Clinical Cancer Research</i> , 2004 , 10, 7965-71	12.9	196
44	c-Myc interacts with hypoxia to induce angiogenesis in vivo by a vascular endothelial growth factor-dependent mechanism. <i>Cancer Research</i> , 2004 , 64, 6563-70	10.1	80
43	CITED4 inhibits hypoxia-activated transcription in cancer cells, and its cytoplasmic location in breast cancer is associated with elevated expression of tumor cell hypoxia-inducible factor 1alpha. <i>Cancer Research</i> , 2004 , 64, 6075-81	10.1	51
42	The transcription factor DEC1 (stra13, SHARP2) is associated with the hypoxic response and high tumour grade in human breast cancers. <i>British Journal of Cancer</i> , 2004 , 91, 954-8	8.7	80

41	Expression of the forkhead transcription factor FOXP1 is associated with estrogen receptor alpha and improved survival in primary human breast carcinomas. <i>Clinical Cancer Research</i> , 2004 , 10, 3521-7	12.9	79
40	Histological quantitation of tumour angiogenesis. <i>Apmis</i> , 2004 , 112, 413-30	3.4	123
39	Phosphorylated KDR is expressed in the neoplastic and stromal elements of human renal tumours and shuttles from cell membrane to nucleus. <i>Journal of Pathology</i> , 2004 , 202, 313-20	9.4	48
38	Vascular endothelial growth factor (VEGF)-A and platelet-derived growth factor (PDGF) play a central role in the pathogenesis of digital clubbing. <i>Journal of Pathology</i> , 2004 , 203, 721-8	9.4	119
37	The presence of a fibrotic focus in invasive breast carcinoma correlates with the expression of carbonic anhydrase IX and is a marker of hypoxia and poor prognosis. <i>Breast Cancer Research and Treatment</i> , 2003 , 81, 137-47	4.4	100
36	The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression. <i>Journal of Pathology</i> , 2003 , 200, 183-94	9.4	166
35	Expression of the cell death genes BNip3 and NIX in ductal carcinoma in situ of the breast; correlation of BNip3 levels with necrosis and grade. <i>Journal of Pathology</i> , 2003 , 201, 573-80	9.4	91
34	Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression. <i>British Journal of Cancer</i> , 2003 , 88, 718-25	8.7	126
33	Breast cancer classification and prognosis based on gene expression profiles from a population-based study. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003 , 100, 10393-8	11.5	1562
32	Expression of the angiopoietins and their receptor Tie2 in human renal clear cell carcinomas; regulation by the von Hippel-Lindau gene and hypoxia. <i>Journal of Pathology</i> , 2002 , 198, 502-10	9.4	82
31	Diagnostic and Prognostic Significance of Tumor Angiogenesis 2002 , 151-176		1
30	Minichromosome maintenance protein 2 expression in normal kidney and renal cell carcinomas: relationship to tumor dormancy and potential clinical utility. <i>Clinical Cancer Research</i> , 2002 , 8, 1075-81	12.9	65
29	VEGF-B expression in human primary breast cancers is associated with lymph node metastasis but not angiogenesis. <i>Journal of Pathology</i> , 2001 , 193, 325-32	9.4	47
28	Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer. <i>Journal of Pathology</i> , 2001 , 195, 236-43	9.4	32
27	Microscopic assessment of angiogenesis in tumors. <i>Methods in Molecular Medicine</i> , 2001 , 46, 29-46		6
26	Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs. <i>Lancet Oncology</i> , 2001 , 2, 278-89	21.7	200
25	Angiogenesis in Mammary Tumors: Quantitation and Relation to Prognosis 2001 , 63-84		1
24	More about: Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma. <i>Journal of the National Cancer Institute</i> , 2000 , 92, 161-2	9.7	10

23	Upregulation of basic fibroblast growth factor in breast carcinoma and its relationship to vascular density, oestrogen receptor, epidermal growth factor receptor and survival. <i>Annals of Oncology</i> , 1999 , 10, 707-13	10.3	68
22	Association of tumor angiogenesis with bone marrow micrometastases in breast cancer patients. <i>Journal of the National Cancer Institute</i> , 1997 , 89, 1044-9	9.7	109
21	Relationship of elevated tumour thymidine phosphorylase in node-positive breast carcinomas to the effects of adjuvant CMF. <i>Annals of Oncology</i> , 1997 , 8, 271-5	10.3	43
20	The epidermal growth factor receptor in breast cancer. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 1997 , 2, 131-41	2.4	40
19	Markers of tumor angiogenesis: clinical applications in prognosis and anti-angiogenic therapy. <i>Investigational New Drugs</i> , 1997 , 15, 15-28	4.3	57
18	Breast cancer angiogenesis--new approaches to therapy via antiangiogenesis, hypoxic activated drugs, and vascular targeting. <i>Breast Cancer Research and Treatment</i> , 1996 , 38, 97-108	4.4	46
17	Prognostic value of angiogenesis in operable non-small cell lung cancer. <i>Journal of Pathology</i> , 1996 , 179, 80-8	9.4	125
16	Tumour angiogenesis. <i>Journal of Pathology</i> , 1996 , 179, 232-7	9.4	117
15	The prognostic value of quantitative angiogenesis in breast cancer and role of adhesion molecule expression in tumor endothelium. <i>Breast Cancer Research and Treatment</i> , 1995 , 36, 219-26	4.4	48
14	Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in normal tissues: an immunohistochemical study. <i>Journal of Pathology</i> , 1995 , 176, 183-90	9.4	162
13	Re: Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma. <i>Journal of the National Cancer Institute</i> , 1995 , 87, 1798-9; author reply 1801-2	9.7	10
12	Quantitation and prognostic value of breast cancer angiogenesis: comparison of microvessel density, Chalkley count, and computer image analysis. <i>Journal of Pathology</i> , 1995 , 177, 275-83	9.4	369
11	Increased expression of CD44v6 and CD44v3 in ulcerative colitis but not colonic Crohn's disease. <i>Lancet, The</i> , 1995 , 345, 1205-9	4.0	69
10	An Immunohistochemical and Prognostic Evaluation of Cathepsin D Expression in 105 Bladder Carcinomas. <i>Journal of Urology</i> , 1995 , 154, 237-241	2.5	19
9	Thymidine phosphorylase is angiogenic and promotes tumor growth. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1995 , 92, 998-1002	11.5	336
8	The epidermal growth factor receptor as a prognostic marker: results of 370 patients and review of 3009 patients. <i>Breast Cancer Research and Treatment</i> , 1994 , 29, 41-9	4.4	130
7	Tumor angiogenesis in node-negative breast carcinomas--relationship with epidermal growth factor receptor, estrogen receptor, and survival. <i>Breast Cancer Research and Treatment</i> , 1994 , 29, 109-16	4.4	152
6	Expression of cathepsin D and estrogen receptor in male breast carcinoma. <i>Human Pathology</i> , 1993 , 24, 148-51	3.7	34

5	Oestrogen receptor and epidermal growth factor receptor expression in male breast carcinoma. <i>Journal of Pathology</i> , 1992 , 166, 13-8	9.4	32
4	Steroid Hormone and Oncoprotein Expression in Male Breast Carcinoma. <i>Journal of Histotechnology</i> , 1991 , 14, 286-286	1.3	
3	Megakaryocytes in myelodysplasia: an immunohistochemical study on bone marrow trephines. <i>Histopathology</i> , 1990 , 17, 69-74	7.3	17
2	Langerhans cells in human lung tumours: an immunohistological study. <i>Histopathology</i> , 1989 , 14, 269-75	7.3	26
1	Second malignant tumors detected by needle aspiration cytology. <i>Cancer</i> , 1983 , 52, 699-706	6.4	11